1834 – Efanesoctocog alfa for routine prophylaxis in patients with haemophilia A

Referral from the National Blood Authority.

Efanesoctocog alfa is a factor VIII replacement treatment. Factor VIII is a protein that helps blood clot. The treatment combines laboratory-made factor VIII with part of another clotting protein called von Willebrand factor and with man-made protein chains called XTEN. 

 

Haemophilia A is a genetic condition that lasts throughout life. People with this condition do not have enough clotting factor VIII, a protein that helps blood clot. As a result, bleeding may be excessive, painful and last a long time. It can happen without a clear cause, after a minor injury, or after major injury or surgery. Most bleeding occurs in the joints, while some occurs in the muscles.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the application is addressing.   

Before providing your input, please read our Privacy Notice for MSAC consultation input to ensure you are comfortable with how we will use your input.  

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Friday 6 November 2026 11:59 pm AEDT
• Pre-MSAC consultation deadline: To be confirmed

For other ways to provide input, see how to have your say.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 10 to 11 December 2026
• ESC meeting: To be confirmed
• MSAC meeting: To be confirmed

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.